Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi.

A novel chemotherapy in development for Chagas' disease targets cruzain, the major cysteine protease of Trypanosoma cruzi. Peptidomimetic inhibitors disrupt the intracellular cycle of the parasite and rescue animals from a lethal infection. Inhibitor killing of parasites results from interruption of autocatalytic cruzain processing and transport to lysosomes, and massive accumulation of precursor protein in the Golgi complex. To further understand the mechanisms of protease processing and transport in this primitive eukaryote, and uncover potential mechanisms for resistance to these drugs, we generated cysteine-protease inhibitor (CPI)-resistant epimastigotes in vitro and investigated the mechanisms involved at the biochemical and structural levels. Resistance to 20-fold the lethal CPI concentration, achieved after a year of gradual drug increase, was accompanied by a modest decrease in growth rate. A marked increase in the number of vesicles trafficking from the Golgi complex to the flagellar pocket occurs in resistant cells. No mature protease reaches lysosomes though accumulation of endocytosed gold particles in lysosomes appears to be normal. Higher molecular mass cruzain species, consistent with complexes of cruzain precursors and inhibitor, are secreted by CPI-resistant parasites into the culture supernatant. Release of these cruzain precursors may be facilitated by an enhanced acidification of trans-Golgi cisternae in resistant parasites. The pH within Golgi cisternae is higher in control epimastigotes and most mature cruzain is lysosomal. Cruzain activity is negligible in CPI-resistant epimastigote extracts compared to the parental clone. Activity is restored following withdrawal of the inhibitor. No cross-resistance to the therapeutic drugs nifurtimox and benznidazole occurred and, conversely, parasites resistant to these drugs were sensitive to CPI. Protease inhibitors are thus potential therapeutical alternatives in cases of nifurtimox/benznidazole resistance. Cumulatively, these results suggest that CPI-resistance induces upregulation of Golgi complex function and post-Golgi secretory pathway, and release of precursors before the enzyme reaches its site of biologic activity.

[1]  M. Ouellette,et al.  New mechanisms of drug resistance in parasitic protozoa. , 1995, Annual review of microbiology.

[2]  P. Wincker,et al.  Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870 , 1996, Science.

[3]  R J Fletterick,et al.  The crystal structure of cruzain: a therapeutic target for Chagas' disease. , 1995, Journal of molecular biology.

[4]  R. Gazzinelli,et al.  Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. , 1998, Molecular and biochemical parasitology.

[5]  F. Conraths,et al.  Juvenile female Litomosoides sigmodontis produce an excretory/secretory antigen (Juv-p120) highly modified with dimethylaminoethanol , 1998, Parasitology.

[6]  P. Matsudaira,et al.  Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. , 1987, The Journal of biological chemistry.

[7]  J. Bonifacino,et al.  Mechanism of Acidification of the trans-Golgi Network (TGN) , 1998, The Journal of Biological Chemistry.

[8]  S. Doty,et al.  Inorganic trimetaphosphatase as a histochemical marker for lysosomes in light and electron microscopy. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  A. Luquetti.  Etiological treatment for chagas disease—The National Health Foundation of Brazil , 1997 .

[10]  A. Mills,et al.  Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. , 1993, Molecular and biochemical parasitology.

[11]  U. Hellman,et al.  Amino acid and carbohydrate composition of a lysosomal cysteine proteinase from Trypanosoma cruzi. Absence of phosphorylated mannose residues. , 1990, Molecular and biochemical parasitology.

[12]  R. Docampo.  Sensitivity of parasites to free radical damage by antiparasitic drugs. , 1990, Chemico-biological interactions.

[13]  J. Dvorak,et al.  Isolate-dependent differences in the oxidative metabolism of Trypanosoma cruzi epimastigotes. , 1990, Molecular and biochemical parasitology.

[14]  M. F. Wiser,et al.  A cryptic protease activity from Trypanosoma cruzi revealed by preincubation with kininogen at low temperatures. , 1997, Biochemical and biophysical research communications.

[15]  D. Dwyer,et al.  Leishmania: immunochemical comparison of the secretory (extracellular) acid phosphatases from various species. , 1993, Experimental parasitology.

[16]  J. Mottram,et al.  Protease Trafficking in Two Primitive Eukaryotes Is Mediated by a Prodomain Protein Motif* , 1999, The Journal of Biological Chemistry.

[17]  I. Larripa,et al.  Assessment of cytogenetic damage in chagasic children treated with benznidazole. , 1988, Mutation research.

[18]  A. J. Parodi,et al.  The presence of complex-type oligosaccharides at the C-terminal domain glycosylation site of some molecules of cruzipain. , 1995, Molecular and biochemical parasitology.

[19]  S. Quan,et al.  Ultrastruct and tartrate-resistant acid phosphatase localization in a T-cell hairy-cell leukemia cell line. , 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  T. Nozaki,et al.  Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi. , 1996, The American journal of tropical medicine and hygiene.

[21]  E. Caler,et al.  A Cytosolic Serine Endopeptidase from Trypanosoma cruzi Is Required for the Generation of Ca2+ Signaling in Mammalian Cells , 1997, The Journal of cell biology.

[22]  S. G. Andrade,et al.  Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. , 1991, Memorias do Instituto Oswaldo Cruz.

[23]  S. L. Gwaltney,et al.  Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases. , 1999 .

[24]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[25]  A. Teixeira,et al.  Cloning and sequencing of tccb, a gene encoding a Trypanosoma cruzi cathepsin B-like protease. , 1998, Molecular and biochemical parasitology.

[26]  H. Riezman,et al.  Morphology of the yeast endocytic pathway. , 1998, Molecular biology of the cell.

[27]  J. Cazzulo,et al.  Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes. , 1987, Molecular and biochemical parasitology.

[28]  S. Goldenberg,et al.  Heterogeneity of metalloprotease expression in Trypanosoma cruzi , 1996, Parasitology.

[29]  R. Neal,et al.  Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  P. Selzer,et al.  Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease. , 1999, The Biochemical journal.

[31]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[32]  M. Mcgrath,et al.  The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. , 1995, Parasitology today.

[33]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[34]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.

[35]  Z. Brener.  Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere. , 1979, Pharmacology & therapeutics.

[36]  V. Turk,et al.  Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. , 1997, Biological chemistry.

[37]  D. Bainton,et al.  Association of alkaline-phosphatase-positive reticulum cells in bone marrow with granulocytic precursors , 1979, The Journal of experimental medicine.

[38]  S. G. Andrade,et al.  Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. , 1985, Bulletin of the World Health Organization.

[39]  A. Romanha,et al.  In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole , 1998, Parasitology.

[40]  E. Segura,et al.  Trypanosoma cruzi: biological characterization of 19 clones derived from two chronic chagasic patients. I. Growth kinetics in liquid medium. , 1982, The Journal of protozoology.

[41]  J. Scharfstein,et al.  Investigation of the substrate specificity of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, through the use of cystatin-derived substrates and inhibitors. , 1996, The Biochemical journal.

[42]  D. Bainton,et al.  Ultrastructural localization of acid phosphatase in rosetted T and B lymphocytes of normal human blood. , 1981, The American journal of pathology.

[43]  C. Craik,et al.  The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. , 1992, The Journal of biological chemistry.

[44]  D. Dwyer,et al.  Radioiodination and identification of externally disposed membrane components of Leishmania tropica. , 1983, Molecular and biochemical parasitology.

[45]  B. Ullman.  Multidrug resistance and P-glycoproteins in parasitic protozoa , 1995, Journal of bioenergetics and biomembranes.

[46]  Ximena Aguilera,et al.  Treatment of chronic Chagas' disease with itraconazole and allopurinol. , 1998, The American journal of tropical medicine and hygiene.

[47]  J. Palmer,et al.  Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. , 1998, Journal of cell science.

[48]  R. Tarleton,et al.  Chagas disease etiology: autoimmunity or parasite persistence? , 1999, Parasitology today.

[49]  L V Kirchhoff,et al.  American trypanosomiasis (Chagas' disease)--a tropical disease now in the United States. , 1993, The New England journal of medicine.